1. Introduction {#s0005}
===============

Glucocorticoids have profound anti-inflammatory and immunosuppressive effects and are successfully used in the treatment of a number of pediatric diseases ([@bb0085]; [@bb0130]). Along the targeted effects of glucocorticoid treatment, glucocorticoids can profoundly affect many parts of the body. Detrimental side-effects on the developing brain have been identified ([@bb0095]). In the brain, the effects of glucocorticoids are mediated by the mineralocorticoid and glucocorticoid receptors by both genomic, epigenomic and rapidly induced non-genomic mechanisms ([@bb0135]; [@bb0255]). Mineralocorticoid receptors are especially abundant in hippocampus and amygdala, while glucocorticoid receptors are more widely distributed throughout the human brain ([@bb0050]; [@bb0105]; [@bb0180]; [@bb0255]). Furthermore, both hippocampus and amygdala play an important role in regulating endogenous cortisol levels ([@bb0110]), and are regarded as cerebral target structures for glucocorticoids ([@bb0155]).

The potentially harmful effects of exogenous glucocorticoids in the brain have so far primarily been studied in relation to exposure perinatally or in adulthood. Perinatal exposure to glucocorticoids has been linked to structural brain changes and neurological and behavioural problems in offspring later in life, including cortical thinning, cerebral palsy, abnormal neurological examination and affective problems ([@bb0100]; [@bb0115]; [@bb0260]). Furthermore, a post-mortem study of preterm-born children found that children prenatally exposed to glucocorticoids had a lower density of hippocampal neurons than non-exposed children ([@bb0275]), an observation that is consistent with findings in animal models ([@bb0220]; [@bb0280]). Glucocorticoid treatment for extra-cerebral diseases in adulthood has been related to smaller amygdala and hippocampal volumes measured during treatment ([@bb0035]; [@bb0040]). The observed smaller hippocampal volumes may, at least partially, be due to a lower density of healthy neurons as suggested by lower hippocampal *N*-acetyl aspartate ratios measured with magnetic resonance spectroscopy ([@bb0035]). Hippocampal and amygdala atrophy has also been found in adults and children with elevated levels of endogenous glucocorticoids due to Cushing\'s disease ([@bb0215]; [@bb0235]). Moreover, magnetic resonance spectroscopy studies in cured Cushing\'s disease patients revealed lower hippocampal *N*-acetyl aspartate and higher glutamate and glutamine levels suggestive of decreased neuronal density and increased glial proliferation ([@bb0250]).

While most studies investigated the impact of glucocorticoids on limbic structures, glucocorticoid treatment may impact other subcortical brain structures as well ([@bb0050]). Notably, exposure to glucocorticoids in the neonatal period has recently been associated with smaller white matter, putamen, caudate nucleus, and globus pallidus volumes in adolescents born extremely premature (\<28 weeks), while differences in hippocampus or amygdala volumes were not observed ([@bb0070]).

In contrast to pre- and perinatal glucocorticoid exposure, studies investigating the long-term effects of exogenous glucocorticoid exposure later in childhood are sparse. This is despite the widespread use of glucocorticoids in the treatment of multiple pediatric diseases ([@bb0095]), and the fact that the brain continues to mature throughout childhood and adolescence as evidenced by in vivo magnetic resonance imaging (MRI) studies ([@bb0045]; [@bb0150]; [@bb0195]). Hippocampal and amygdala volumes increase during late childhood and level off during adolescence. Caudate nucleus, putamen and nucleus accumbens appear to decrease in volume during late childhood and adolescence into early adulthood ([@bb0230]; [@bb0295]). Studies employing diffusion-weighted imaging (DWI) to assess brain tissue microstructure revealed that subcortical grey matter structures undergo developmental changes, as indexed by decreasing mean diffusivity (MD) ([@bb0190]). MD reflects the magnitude of water diffusion and is negatively proportional to the amount of cell membranes and cellular structures ([@bb0025]). Notably, caudate nucleus MD has been reported to decrease well into adulthood, while putamen and globus pallidus MD appear to level off to adult levels in late adolescence ([@bb0190]). Thus, both volumetric and microstructural maturation occurs in subcortical regions during childhood and adolescence, which could potentially be affected by glucocorticoid exposure in this period of life.

The present study aimed to investigate the possible long-term effects of previous glucocorticoid treatment during childhood on the volume and microstructure of subcortical grey matter structures. To this end, we compared child and adolescent patients, previously treated with glucocorticoids for nephrotic syndrome or rheumatic disease, with healthy controls. We included these two different extra-cerebral pediatric diseases with the aim to control for potential disease-related effects. In previous work, we observed that these patients had lower verbal intellectual abilities ([@bb0140]) and smaller total brain volumes as compared to healthy controls ([@bb0145]). Furthermore, the children treated with glucocorticoid showed sex-dependent differences in endogenous cortisol profiles compared to healthy controls, with girls having higher cortisol awakening response (CAR) and boys having higher cortisol levels during the day ([@bb0285]). In the present study, our primary hypothesis was that patients, as compared to healthy controls, would have smaller hippocampal and amygdala volumes independent of differences in total brain volume. Secondary, we expected that patients would differ from controls in hippocampal and amygdala MD. Furthermore, we examined if patients differed from controls in putamen, caudate nucleus, or nucleus accumbens volume or MD. Finally, within patients we examined for possible doses-response associations between glucocorticoid treatment variables and subcortical brain structure volume or MD.

2. Material and methods {#s0010}
=======================

The participants in the present study are the same as in our recent study investigating the effects on glucocorticoid treatment on global structural brain measures ([@bb0145]). Therefore, if identical, information on participants, clinical characteristics and background variables is presented between quotation marks followed by the reference to the previous article.

2.1. Participants {#s0015}
-----------------

"A total of 30 children and adolescents previously treated with glucocorticoid because of either rheumatic disease or nephrotic syndrome, recruited from outpatient pediatric clinics, and 30 matched healthy controls, recruited from public schools, were included in the present study. Patient and control groups were matched on average age, gender, and parent education. The patients were between 7.0 and 16.1 years of age and consisted of 8 boys and 22 girls. The controls were between 7.0 and 15.6 years of age and consisted of 11 boys and 19 girls. The subjects were part of a larger cohort, which has been described in detail elsewhere ([@bb0145]). Of the initial thirty-eight included patients, seven did not complete MRI scanning and one was excluded because of poor image quality due to motion artefacts. Thus, 30 patients with good-quality T1-weighted scans were included in the current study. Of the initially forty-two included healthy controls, five participants did not complete scanning and one control was excluded because of motion artefacts. Thus, good-quality scans were available for 36 healthy controls. To ensure that group averages for included patients were matched to controls on age, gender, and parent education, we excluded five boys and one girl with a mean age of 11.8 years and mean parental education of 17.1 years. Exclusion was done blinded to the MRI data and before any processing of MRI images or statistical analyses. There were no significant differences in age, gender, or parental education between the initial included subjects and the subjects with good-quality MRI scan (all *P* values ≥0.30).

Only children and adolescents without neurological or psychiatric diseases or preterm birth were included. Controls were required to be healthy and without previous systemic glucocorticoid treatment. Only patients without current glucocorticoid treatment at the time of the study were included. The study was ethically approved by the Scientific Ethical Committee, Capital Region, Denmark (H-KF-01- 131/03 and addendum of June 2009). Written informed consent was obtained from parents of all participants" ([@bb0145]). The study was conducted in accordance with the Helsinki declaration.

2.2. Clinical characteristics {#s0020}
-----------------------------

"Patients\' medical charts were reviewed, and diagnosis and glucocorticoid treatment data were collected" ([@bb0145]). "The study included 11 patients with nephrotic syndrome and 19 with rheumatic disease. The group of children with nephrotic syndrome included idiopathic nephrotic syndrome (n = 5), nephrotic syndrome associated with Henoch-Schönlein purpura (n = 4), and nephrotic syndrome associated with glomerulonephritis (n = 2). The group of children with rheumatic disease included systemic juvenile idiopathic arthritis (n = 1), polyarticular juvenile idiopathic arthritis (n = 3), oligoarticular juvenile idiopathic arthritis (n = 8), enthesitis-related juvenile idiopathic arthritis (n = 2), juvenile dermatomyositis (n = 3), mixed connective tissue disease (n=1), and systemic lupus erythematosus (n = 1)." ([@bb0145]). Treatment variables are presented in [Table 2](#t0010){ref-type="table"}. "The primary treatment variable was cumulative prednisolone equivalent glucocorticoid dose (mg/kg). In addition, median daily dose (mg/kg/day), median treatment age, and time since treatment (i.e., time elapsed from treatment termination to assessment) were registered. Glucocorticoids were administered orally. However, five patients (one with nephrotic syndrome and four with rheumatic disease) received intravenous glucocorticoid high-dose therapy (pulse therapy) in addition to oral glucocorticoid treatment, which constituted between 36 and 64% of their cumulative dose" ([@bb0145]). Twelve patients received non-glucocorticoid treatment at the time of assessment, which included TNF-α-inhibitors (n= 7), methotrexate (n= 3), anti-hypertensive drugs (n = 2), interleukin-1-inhibitor (n = 1), and non-steroid anti-inflammatory drugs (n = 1).

2.3. Background variables {#s0025}
-------------------------

"The assessment of background and cognitive variables are described in detail elsewhere ([@bb0140]). Height, weight, head circumference, and pubertal development (Tanner staging) were measured. Current and previous physical activity, stressful life events, and behavioral problems were assessed by questionnaires" ([@bb0145]). Verbal intellectual ability was estimated using the verbal comprehension index (VCI) based on the information and vocabulary subtests from the Wechsler Intelligence Scale for Children III ([@bb0240]). Endogenous cortisol levels were measured by collecting saliva samples using oral swabs (Salimetrics Oral Swab, Salimetrics, Pennsylvania, USA) on two consecutive regular schooldays. Measures of interest were CAR and daily cortisol levels assessed by calculating area under the curve, both expressed as averages of the two sample days. For a detailed description of how measures were calculated see ([@bb0285]).

2.4. Image acquisition {#s0030}
----------------------

Structural MRI of participants was obtained on a 3 T Siemens Magnetom Trio magnetic resonance scanner (Siemens, Erlangen, Germany) using an eight-channel head coil (Invivo, Florida, USA). High-resolution whole brain 3D T1-weighted Magnetization Prepared Rapid Gradient Echo (MPRAGE) images were acquired (TE = 3.04 ms, TR = 1550 ms, matrix = 256 × 256 mm, 192 sagittal slices, no gap, 1 mm^3^ voxels). Whole brain DWI was acquired using a twice-refocused balanced spin-echo sequence to minimize distortions by eddy currents ([@bb0245]). We acquired 10 non-DW images (b = 0) and 61 DW images, which were encoded along independent collinear diffusion gradient orientations (TR = 8200 ms, TE = 100 ms, FOV = 220 × 220 mm^2^, matrix = 96 × 96, GRAPPA (GeneRalized Autocalibrating Partial Parallel Acquisition): factor 2, 48 lines, 61 perpendicular slices, no gap, 2.3 mm^3^ voxels). A gradient echo field map was obtained to correct for B~0~ field distortions ([@bb0010]) (TR = 530 ms, TE\[1\] = 5.19 ms and TE\[2\] = 7.65 ms, FOV = 256 × 256 mm^2^, matrix = 128 × 128, 47 perpendicular slices with no gap, 2 × 2 × 3 mm^3^ voxels). Both the DWI and the gradient field map scans were oriented parallel to the anterior-posterior commissure line. All images were inspected for quality. All T1-weighted images were evaluated by a neuroradiologist and deemed without clinical pathology.

2.5. Image preprocessing {#s0035}
------------------------

### 2.5.1. Preprocessing of T1-weighted images {#s0040}

T1-weighted images were processed using the VBM5.1 toolbox implemented in SPM8 ([www.fil.ion.ucl.ac.uk/spm/software/spm8](http://www.fil.ion.ucl.ac.uk/spm/software/spm8){#ir0005}) running in Matlab R2013b. Initially, images were gradient unwarped to correct for non-linear spatial distortions in the scanner gradients ([@bb0165]). After a 6 parameter rigid transformation to MNI-space, grey and white matter and CSF were segmented with VBM5.1 using default settings and the Hidden Markov Random Field method ([@bb0090]). A brain mask generated using the graph-cut mask function was applied to the segmented tissue images to remove extra-cerebral tissue voxels. Tissue segmentations were visually inspected to ensure quality before warping the grey and white matter images with DARTEL (Diffeomorphic Anatomic Registration Through Exponentiated Lie algebra) to achieve high-dimensional inter-individual alignment ([@bb0015]). Subsequently, the individual DARTEL deformation flow fields were applied to individual masked brain tissue images in order to bring them into a common "DARTEL" space.

### 2.5.2. Pre-processing of diffusion weighted images {#s0045}

DW images were pre-processed using pipelines implemented in Matlab, using SPM8 routines as well as FSL 5.0.1 (<http://www.fmrib.ox.ac.uk/>). For each individual, DW images were co-registered to the average of all b0 images (no reslicing). Subsequently, DWI images were corrected for geometric distortions due to B~0~ field inhomogeneity and gradient non-linearity ([@bb0010]; [@bb0165]) and transformed into MNI orientation (no scaling) using a single tri-linear interpolation. The diffusion orientations were adjusted to account for any rotation applied during registration ([@bb0200]). To exclude non-brain voxels DW images were masked with a brain mask that was created by applying the Brain Extraction Tool (BET) implemented in FSL ([@bb0265]) on each non-DW image and taking the median of the resulting masks. The diffusion tensor was fitted using a least-squares-fit by non-linear optimization employing a Levenburg-Marquardt algorithm ([@bb0160]) and constrained to be positive definite by fitting its Cholesky decomposition implemented in Camino ([@bb0080]). Fractional anisotropy (FA) and mean diffusivity (MD) images were calculated. MD was calculated as the mean of diffusivities along three perpendicular axes (λ~1~, λ~2~, λ~3~) ([@bb0020]). FA images were used to calculate the best possible (non-linear) registration between MD images and individual T1-weighted anatomical images as part of the procedure to extract individual ROI MD (see below).

### 2.5.3. Grey matter regions-of-interest {#s0050}

Participants\' T1-weighted images were warped into "DARTEL" space using individual DARTEL flow fields. Next, resulting images were averaged to create a T1-weighted study template, on which grey matter regions-of-interest (ROIs) were delineated using FSLView ([www.fsl.fmrib.ox.ac.uk/fsl/fslview](http://www.fsl.fmrib.ox.ac.uk/fsl/fslview){#ir0015}). Using the inverse DARTEL flow fields ROIs were transformed into each individual\'s T1-weighted image native space and edited to ensure their fit while blinded to subject identity.

The left and right hippocampi and amygdalae were drawn using previously described guidelines ([@bb0120]; [@bb0210]). The hippocampal ROI included the cornu ammonis, dentate gyrus, alveus, and part of subiculum, while the fimbria and parahippocampal gyrus were excluded. For the striatal ROIs, striatal cell bridges were not included. The accumbens was delineated on the first axial slice where the caudate nucleus and putamen joined inferiorly and was not allowed to extend posteriorly beyond the anterior commissure. In coronal view, the accumbens was separated from the caudate nucleus by a straight line connecting the most inferior part of the frontal horn of the lateral ventricle to the most inferior part of the internal capsule. The border between accumbens and putamen was drawn as a straight vertical line from the most inferior part of the internal capsule. The caudate nucleus was delineated posteriorly until the posterior commissure. The ROIs are shown in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1Regions-of-interest.Regions-of-interest overlaid on the average of warped T1-weighted images.Fig. 1

To extract individual ROI MD, we used the following procedure to minimize white matter and CSF partial volume effects and maximizing sampling within grey matter tissue. Firstly, ROIs were eroded using a 1 mm Gaussian kernel, thereby excluding an approximately one-voxel thick layer from the outer border of the ROI. Secondly, for each individual, the FA image was warped to the T1-weighted image in native space using the linear FLIRT and non-linear FNIRT registration algorithms in FSL. The resulting deformation fields were then applied to the MD images and the anatomical fit was visually inspected. Thirdly, using the inverse deformation the eroded ROIs residing in T1-weighted native space were transformed to diffusion-weighted native image space using tri-linear interpolation and binarized using a threshold of 0.5. The anatomical match was visually inspected. Fourthly, the binary ROIs were multiplied by the participant\'s perpendicular diffusivity image, and then thresholded at a perpendicular diffusivity of \<0.0011, in order to exclude any remaining CSF partial volume voxels. Finally, mean MD values were extracted from the final ROIs for each subject. To estimate individual global MD within grey and white matter, mean MD was calculated within a whole brain mask created by thresholding individual perpendicular diffusivity images \<0.0009 to exclude CSF and CSF partial volume voxels.

To obtain estimates of total brain volume (TBV) for use in the statistical analyses, we used the automated calculated TBV within FreeSurfer, a freely available software package for structural and functional image analyses (<https://surfer.nmr.mgh.harvard.edu>). Processing of individual T1-weighted images with FreeSurfer followed standard procedures and is described in detail elsewhere ([@bb0145]). The pial and grey-white matter surfaces generated by FreeSurfer were visually inspected and corrected following standard guidelines where necessary. The TBV included supra- and infratentorial volumes of grey and white matter, while ventricles, brain-stem and choroid plexus were excluded ([www.freesurfer.net/fswiki/MorphometryStats](http://www.freesurfer.net/fswiki/MorphometryStats){#ir0025}).

2.6. Statistics {#s0055}
---------------

The statistical analyses for demographic and background variables are largely the same as in our previous work ([@bb0145]). Therefore, wherever information is the same it is presented between quotation marks, followed by the reference to the article in which the information can be found. SPSS 20 (SPSS, IBM Corp., USA) was used for statistical analyses.

### 2.6.1. Demographic and background variables {#s0060}

***"***A χ2-test tested for possible gender differences. The Shapiro--Wilk test was used to test whether continuous variable distributions deviated from a normal distribution. Independent samples t-tests tested for group differences in normally distributed variables, including age and parent education. Group differences in the background, behavioral, and cognitive variables, height, weight, head circumference, verbal comprehension index (VCI), perceptual organization index, Tanner stage, physical activity, stressful life events, behavioral problems, and pattern recognition memory were evaluated using multiple linear regression with age and gender as control variables. The lifetime stressful life event (SLE) questionnaire includes two statements regarding somatic disease (i.e., "my child had a medical diagnosis" and "my child was severely ill or injured"), which patients and controls are expected to differ on. Therefore, we report stressful life events with and without these disease-related questions. Within patients, Mann--Whitney *U* tests tested for potential gender- and disease-group differences in treatment variables" ([@bb0145]). CAR and the daily cortisol levels were evaluated using multiple linear regression with age and gender as control variables.

### 2.6.2. Subcortical brain measures {#s0065}

Potential differences between patients and controls in ROI volume or ROI MD were evaluated using multiple linear regression analyses. All assumptions for linear regression were fulfilled. Adjusted mean differences (AMD) are reported i.e. difference between groups in ROI volumes and ROI MD after controlling for all other predictors in the regression model.

Our primary hypothesis was that patients would have smaller left and right hippocampal and amygdala volumes compared to controls and that this difference would be independent of previously observed group differences in whole brain volume. Secondary, we expected that patients as compared to controls would differ in hippocampus and amygdala MD. ROI volume or ROI MD were used as dependent variables, and group (controls versus patients), age and gender were used as independent prediction variables. The anatomic specificity of observed associations was assessed by adding TBV in models predicting ROI volume, and global MD in models predicting ROI MD. Hippocampus and amygdala volume and MD were analyzed unilaterally since study findings suggest lateralized relations between glucocorticoids and limbic structures ([@bb0055]; [@bb0205]). Bilateral measures were used for testing group differences in putamen, caudate nucleus or nucleus accumbens volume or MD. Finally, we explored group by gender interactions to evaluate potential gender specific differences between patients and controls controlling for age and global measures. Pertinent to a significant interaction, we tested group differences for each gender separately.

### 2.6.3. Associations with glucocorticoid treatment variables {#s0070}

Contingent on finding significant group differences in ROI volume or ROI MD, adjusted for global measures, we investigated for associations between ROI volume or ROI MD and treatment variables in patients, controlling for age, sex and global measure. First, we tested if ROI volume or ROI MD was associated with cumulative glucocorticoid dose. Second, we tested for associations with median daily dose, treatment duration, median treatment age, or time since treatment. Third, we tested for a cumulative dose by median treatment age interaction, controlling for age, sex and global measure, cumulative dose, median treatment age, and time since treatment. The cumulative dose by median treatment age interaction tested whether the effect of glucocorticoid treatment differed depending on the age at which children received treatment.

### 2.6.4. Planned follow-up analyses {#s0075}

To evaluate if observed group differences were present in each of the disease groups, we contrasted rheumatic disease patients and nephrotic syndrome patients separately with healthy controls, controlling for age, gender, and TBV or global MD.

Since patients had significant lower VCI scores than controls (see under results), we investigated the possible relationship between VCI and those volume and MD measures for which controls and patients significantly differed from each other. Firstly, VCI was predicted with brain measure controlling for group, age, gender and global measure. Secondly, we tested for possible group by VCI interactions on ROI volume and ROI MD, controlling group, age, gender, VCI and global measure.

For the primary hypotheses concerning left and right hippocampal and amygdala volume, we used a Bonferroni corrected *p*-value of 0.013 (α = 0.05/4). Since this, to our knowledge, is the first study to investigate the possible long-term impact of glucocorticoid treatment during childhood on subcortical grey matter structures, we were interested to identify potential group differences and associations that can be tested in future studies. Therefore, in all subsequent analyses we considered effects with *p*-values lower than 0.05 of interest.

3. Results {#s0080}
==========

Results on demographic data and background variables (except CAR and daily cortisol levels) are the same as presented in our previous article on global brain measures ([@bb0145]). These results will be presented between quotation marks followed by the reference to the previous article and the page at which the information can be found.

3.1. Missing data {#s0085}
-----------------

There was missing data for measures of CAR and daily cortisol level (one female patient with rheumatic disease), current physical activity (two female patients with rheumatic disease and one male control), previous physical activity (two female patients with rheumatic disease) and DWI scans (two controls: one boy, one girl, and three female patients with rheumatic disease).

3.2. Demographic data and background variables {#s0090}
----------------------------------------------

Demographic variables are presented in [Table 1](#t0005){ref-type="table"}. Age, gender, and parental education were not significantly different between controls and all patients or between controls and the separate disease groups. Furthermore, comparisons between the two patient groups revealed no significant differences in age (*t* = 0.12, *p* = .91), gender (*p* = .08), or parent education (*t* = 0.54, *p* = .59).Table 1Demographic variables.Table 1ControlsAll patientsNephrotic syndromeRheumatic disease(*n* = 30)(n = 30)(*n* = 11)(*n* = 19)Gender (boys/girls)11/198/225/63/16 *p*-Value*NAp* = .405*p* = .609*p* = .115Age (years) Mean (SD)11.9 (2.4)12.5 (2.2)12.6 (2.2)12.4 (2.3) Range7.0--15.67.0--16.18.2--16.17.0--15.6 *p*-Value*NAt* = −0.99, *p* = .327*t* = −0.820, *p* = .417*t* = −0.809, *p* = .424Parental education (years) Mean (SD)14.5 (1.6)14.0 (2.0)14.25 (2.7)13.8 (1.5) Range11.0--16.59.0--17.09.0--17.011.5--17.0 *p*-Value*NAt* = 1.00, *p* = .320*t* = 0.282, *p* = .780*t* = 1.356, *p* = .182[^1]

"Patients had significantly lower weight and height in comparison with control. Head circumference, although lower, was not significantly different between groups. In agreement with our findings in the larger cohort, patients had significantly lower VCI compared with that in the controls, whereas there was no difference regarding the perceptual organization index, memory performance, or behavioural problems ([@bb0140]). Patients and controls did not significantly differ in pubertal development, physical activity, or stressful life events in the preceding year. In accordance with our previous findings in a larger cohort ([@bb0140]), the number of stressful life events during the child\'s entire lifetime was higher in patients compared with that in controls; however, after exclusion of disease-related questions, this difference was no longer present" ([@bb0145], [Table 2](#t0010){ref-type="table"}, page 807). Patients and controls did not significantly differ in CAR (Patients: Mean (standard deviation (SD)) = 0.33 (0.03); Controls: Mean (SD) = 0.30 (0.02); β = 0.13, *p* = .36) or daily cortisol (in nmol/l/min; Patients: Mean (SD) = 4.01 (0.38); Controls: mean (SD) = 3.87 (0.24); β = 0.02, *p* = .91).Table 2Glucocorticoid treatment variables.Table 2Treatment variablesAll patientsRheumatic diseaseNephrotic syndromep^§^GirlsBoysp^\#^Median treatment age years7.0 (1.9--12.3)6.9 1.9--12.3)7.1 (4.5--10.5).407.1 (1.9--12.3)7.0 (5.1--9.8).99Cumulative dose mg/kg157.8 (20.8--580.5)102.8 (20.8--580.5)298.8 (118.6--514.2)***.03***146.6 (20.8--580.5)237.5 (73.5--514.2).50Median daily dose mg/kg/day0.2 (0.1--2.1)0.2 (0.1--1.1)0.6 (0.1--2.1)***.03***0.2 (0.1--1.1)0.6 (0.1--2.1)***.05***Treatment duration years1.0 (0.1--5.7)1.1 (0.1--5.7)0.8 (0.3--3.9).500.8 (0.1--5.7)1.1 (0.5--1.8).95Time since treatment years4.0 (0.2--8.9)3.6 (0.2--6.8)4.6 (0.6--8.9).553.4 (0.2--6.8)5.0 (2.4--8.9)***.02***[^2]

3.3. Treatment variables {#s0095}
------------------------

Treatment variables and the results of statistical analyses comparing children with nephrotic syndrome with children with rheumatic disease and comparing boys and girls are presented in [Table 2](#t0010){ref-type="table"}. Children with nephrotic syndrome received significant higher cumulative dose and median daily dose of glucocorticoids than children with rheumatic disease. Disease groups did not differ on any of the other treatment variables. Additionally, patient boys had significantly longer time since treatment and received higher median daily doses than patient girls. Boys and girls did not differ in the remaining treatment variables. Disease group by gender interaction effects were absent (*p*-values \>.11).

3.4. Subcortical brain measures {#s0100}
-------------------------------

Measures of ROI volume and ROI MD for controls and patients and patient groups separately are presented in [Table 3](#t0015){ref-type="table"}. Results of multiple regression analyses of volume and MD are presented in [Table 4](#t0020){ref-type="table"} and [Table 5](#t0025){ref-type="table"}, respectively.Table 3Volume and MD for ROIs in controls, patients and the separate disease groups.Table 3MeasureHemisphereControlsAll patientsRheumatic diseaseNephrotic syndromeHippocampal volumeRight2352 ± 2762186 ± 1962188 ± 2122182 ± 176Left2265 ± 3002181 ± 2172178 ± 2042214 ± 245Hippocampal MDRight903 ± 16892 ± 18893 ± 13890 ± 24Left877 ± 17872 ± 22873 ± 22870 ± 22Amygdala volumeRight1234 ± 1131193 ± 1281190 ± 1271198 ± 135Left1197 ± 1101162 ± 1091154 ± 1151177 ± 101Amygdala MDRight839 ± 21838 ± 16837 ± 15840 ± 17Left827 ± 23821 ± 20819 ± 21823 ± 19Putamen volumeBilateral8721 ± 8088156 ± 6958053 ± 6078305 ± 814Putamen MD797 ± 13793 ± 16778 ± 16801 ± 14Caudate nucleus volumeBilateral7637 ± 9207404 ± 8447282 ± 6847582 ± 1045Caudate nucleus MD798 ± 22793 ± 19786 ± 16802 ± 20Accumbens volumeBilateral505 ± 61493 ± 58490 ± 47498 ± 74Accumbens MD835 ± 20831 ± 30810 ± 32837 ± 27Total brain volume (cm^3^)*NA*1264 ± 1081201 ± 1041185 ± 1121230 ± 88Whole brain MD*NA*800 ± 16796 ± 14792 ± 11801 ± 15[^3]Table 4Results for multiple regression analyses of ROI volume.Table 4ROIModelGroupAgeGenderTBV*R*^*2*^~*adj*~*Fpβpβpβpβp*Right hippocampus10.093.0***.04***−0.31***.018***[a](#tf0005){ref-type="table-fn"}−0.05.69−0.17.1920.24.7***.003***−0.21.10−0.08.50−0.08.540.37***.005***Left hippocampus1−0.020.62.60−0.15.280.09.51−0.06.6720.153.61***.01***−0.02.870.5.680.06.650.46***.001***Right amygdala10.052.11.11−0.15.240.08.56−0.25.0620.4512.93***2\*10***^***−7***^0.03.760.02.84−0.08.440.68***4\*10***^***−8***^Left amygdala10.062.12.10−0.16.220.16.20−0.21.1220.4311.91***5\*10***^***−7***^0.02.840.11.27−0.04.690.65***1\*10***^***−7***^Putamen10.175.15***.003***−0.39***.002***[b](#tf0010){ref-type="table-fn"}−0.04.74−0.21.0920.5821.37***5\*10***^***−10***^−0.20***.026***[c](#tf0015){ref-type="table-fn"}−0.10.27−0.04.700.68***8\*10***^***−10***^Caudate nucleus10.001.00.40−0.20.128−0.06.640.05.6820.5821.53***10\*10***^***−11***^0.02.84−0.13.140.26***.005***0.81***3\*10***^***−12***^Nucleus accumbens10.031.59.20−0.13.31−0.05.70−0.23.0820.297.06***.0001***0.02.87−0.10.40−0.09.440.56***2\*10***^***−5***^[^4][^5][^6][^7]Table 5Results for multiple regression analyses of ROI mean diffusivity (MD).Table 5ROIModelGroupAgeGenderTBV*R*^*2*^~*adj*~*Fpβpβpβpβp*Right hippocampus10.164.49***.007***−0.26***.044***[a](#tf0020){ref-type="table-fn"}−0.32***.015***−0.10.4220.245.35***.001***−0.28***.027***[b](#tf0025){ref-type="table-fn"}−0.02.900.08.520.42***.014***Left hippocampus10.072.45.07−0.8.57−0.33***.016***−0.01.9620.102.51***.05***−0.08.53−0.13.480.01.950.29.12Right amygdala10.329.54***4\*10***^***−5***^0.11.36−0.61***3\*10***^***−6***^−0.18.1220.337.60***7\*10***^***−5***^0.10.39−0.47***.005***−0.17.140.19.23Left amygdala10.204.27***.009***−0.08.54−0.34***.011***−0.30***.021***20.153.31***.018***−0.08.53−0.25.17−0.29***.026***0.13.47Putamen10.031.56.21−0.12.38−0.22.120.10.4720.4511.96***7\*10***^***−7***^0.15.160.42***.006***0.15.150.89***1\*10***^***−7***^Caudate nucleus10.215.80***.002***−0.05.67−0.47***.0004***0.12.3520.4411.68***9\*10***^***−7***^−0.07.500.01.950.15.140.67***2\*10***^***−5***^Nucleus accumbens1−0.030.54.66−0.06.68−0.12.400.09.5220.122.92***.030***−0.07.580.27.140.12.350.56***.003***[^8][^9][^10]

### 3.4.1. Primary analyses {#s0105}

#### 3.4.1.1. Hippocampal and amygdala volume {#s0110}

Patients had smaller right hippocampal volumes compared to controls (AMD = −153.3 mm^3^; 95% CI = −280 -- -27). This difference was not statistically significant when correcting for multiple comparisons. (α = 0.05/4 = 0.013). Nevertheless, we corrected for TBV to evaluate if smaller hippocampal volumes would show some anatomical specificity i.e. if the effect remained or became more outspoken. However, neither was the case (AMD = −102.8 mm^3^; 95% CI = −226--21). Groups did not differ in left hippocampal volume. We did not find any significant group by gender interaction effects (right: β = 0.06, *p* = .63 and left: β = 0.10, *p* = .44).

Patients and controls did not significantly differ in left or right amygdala volume without or with correction for TBV. There was some indication for a group by gender interaction for both left (β = 0.22, *p* = .035) and right amygdala (β = 0.19, *p* = .066) volumes. These interactions were due to patient boys having smaller volumes than healthy control boys, while patient and control girls did not differ from each other.

### 3.4.2. Secondary analyses {#s0115}

#### 3.4.2.1. Hippocampal and amygdala MD {#s0120}

Patients had lower right hippocampal MD as compared to controls (AMD = −9.3 × 10^−6^ m^2^/s; 95% CI = −18 × 10^−6^ to −0.3 × 10^−6^). This group difference remained when controlling for global MD (AMD = −9.7 × 10^−6^ m^2^/s; 95% CI = −18 × 10^−6^ to −1 × 10^−6^; [Fig. 2](#f0010){ref-type="fig"}A). Patients and controls did not statistically differ in left hippocampal MD. Group by gender interactions were absent (right hippocampus: β = 0.23, *p* = .68, left hippocampus: β = −0.06, *p* = .67).Fig. 2Group differences in ROI MD and volume.Partial regression plots for differences between controls and patients in (A) right hippocampal mean diffusivity adjusted for age, gender and global MD, and (B) bilateral putamen volume adjusted for age, gender and total brain volume. The horizontal dashed lines represent the group mean. MD: mean diffusivity. Note that the partial regression plots display the model residuals and thus render values arbitrary.Fig. 2

Patients and controls did not significantly differ in left or right amygdala MD without or with correction for global MD. Group by gender interactions were absent (left amygdal: β = 0.12, *p* = .39 and right amygdala: β = 0.15, *p* = .22).

3.5. Explorative analyses {#s0125}
-------------------------

### 3.5.1. Putamen, caudate nucleus and nucleus accumbens volume {#s0130}

Patients had significantly smaller putamen volume as compared to controls (AMD = −675 mm^3^; 95% CI = −1091 to −259) and this group difference remained after controlling for TBV (AMD = −353 mm^3^; 95% CI = −662 -- -44; [Fig. 2](#f0010){ref-type="fig"}B). We did not find a significant group by gender interaction (β = 0.04, *p* = .69).

Patients and controls did not significantly differ in caudate nucleus or nucleus accumbens volumes with or without correction for TBV. Likewise, no significant group by gender interactions were observed (caudate nucleus: β = −0.07, *p* = .46; nucleus accumbens: β = 0.02, *p* = .90).

### 3.5.2. Putamen, caudate nucleus and nucleus accumbens MD {#s0135}

Patients and controls did not significantly differ in putamen, caudate nucleus or nucleus accumbens MD. We did not find any significant group by gender interactions (putamen: β = 0.004, *p* = .97, caudate nucleus: β = 0.05, *p* = .63; nucleus accumbens: β = 0.12, *p* = .38).

3.6. Planned follow-up analyses {#s0140}
-------------------------------

### 3.6.1. Right hippocampal MD {#s0145}

#### 3.6.1.1. Associations with glucocorticoid treatment variables within patients {#s0150}

Within patients, right hippocampal MD was not significantly associated with cumulative dose (β = −0.27, *p* = .17). However, we found a positive association between right hippocampal MD and the time elapsed since termination of treatment (β = 0.57, *p* = .016, [Fig. 3](#f0015){ref-type="fig"}A), suggesting that the longer time since patients received glucocorticoids the more they resembled the control group. Median daily dose, treatment duration, median treatment age, or the cumulative dose by median treatment age interaction were not significantly associated with right hippocampal MD (p\'s \> 0.1). Excluding the five individuals who received pulse therapy did not affect the above findings.Fig. 3Associations between treatment variables and ROI MD and volume.Partial regression plots with solid lines representing the linear model slope and dashed lines representing the 95% confidence intervals. A) Association between right hippocampal MD and the time elapsed since termination of glucocorticoid treatment, adjusted for age, gender, and global MD. B) Association between putamen volume and the median treatment age adjusted for age, gender, and total brain volume. Note that the partial regression plots render values to be arbitrary.Fig. 3

#### 3.6.1.2. Comparing disease groups separately to healthy controls {#s0155}

Follow-up analyses investigating for group differences in right hippocampal MD for each disease group separately, controlling for age, gender and global MD, revealed that children with nephrotic syndrome (β = −0.39; *p* = .005; AMD = −16.4 × 10^−6^; 95% CI = −27 × 10^−6^ to −5 × 10^−6^) but not children with rheumatic disease (β = −0.17; *p* = .23; AMD = −2.8 × 10^−6^; 95% CI = −7 × 10^−6^--2 × 10^−6^) showed lower right hippocampal MD as compared to controls. Nevertheless, the observed positive association between time since treatment and right hippocampal MD was present in both patient groups (nephrotic syndrome: β = 0.48, *p* = .052 and rheumatic disease: β = 0.58, *p* = .059).

#### 3.6.1.3. Associations with verbal comprehension index {#s0160}

VCI was still significantly lower in patients than controls after controlling for right hippocampal MD, and there was no apparent association between right hippocampal MD and VCI (Group: β = −0.46, *p* = .001; Right hippocampal MD: β = 0.13, *p* = .38; Age: β = 0.17, *p* = .33; Gender: β = 0.05, *p* = .67; Global MD: β = −0.02, *p* = .91). Moreover, we found no significant group by VCI interaction effect on right hippocampal MD (β = 0.41, *p* = .36).

### 3.6.2. Putamen volume {#s0165}

#### 3.6.2.1. Associations with glucocorticoid treatment variables within patients {#s0170}

Putamen volume was not associated with cumulative dose (β = −0.19, *p* = .14), median daily dose, treatment duration, nor time since treatment (p\'s \> 0.26). However, putamen volume was negatively associated with median treatment age (β = −0.31, *p* = .03; [Fig. 3](#f0015){ref-type="fig"}B). Putamen volume was not associated with cumulative dose by median treatment age (*p* \> .7). Excluding individuals who received pulse therapy did not affect the above findings.

#### 3.6.2.2. Comparing disease groups separately to healthy controls {#s0175}

Analyses revealed that the observed group difference in putamen volume was present in children with rheumatic disease (β = −0.25; *p* = .02; AMD = −446 mm^3^; 95% CI = −818 -- -74), but not in children with nephrotic syndrome (β = −0.13; *p* = .26; AMD = −247 mm^3^; 95% CI = −686--193). Furthermore, the observed negative association between median treatment age and putamen volume was present in the children with rheumatic disease (β = −0.44, *p* = .015), while absent in children with nephrotic disease (β = 0.08, *p* = .84).

#### 3.6.2.3. Associations with verbal comprehension index {#s0180}

VCI was still significantly lower in patients than controls after controlling for putamen volume, and there was no apparent relationship between putamen volume and VCI (Group: β = −0.48, *p* = .0004; Putamen volume: β = 0.07, *p* = .70; Age: β = 0.22, *p* = .07; Gender: β = 0.06, *p* = .63; TBV; β = 0.18, *p* = .30). There was no group by VCI interaction (β = −0.01, *p* = .99).

4. Discussion {#s0185}
=============

To the best of our knowledge the present study is the first to describe a possible relationship between extra-cerebral diseases treated with glucocorticoids during childhood and adolescence, and differences in limbic and striatal grey matter structure volume and microstructure in children and adolescents. Contrary to our expectations, patients did not differ from controls in hippocampal or amygdala volumes, as the initially observed smaller right hippocampal volumes in patients as compared to healthy did not survive correction for multiple comparisons. Furthermore, exploring if the uncorrected group difference showed anatomical specificity, by correcting for TBV, revealed this likely not to be the case. Nevertheless, patients displayed lower right hippocampal MD than healthy controls, a difference that remained when accounting for whole brain MD. Although lower right hippocampal MD was most prominent in children with nephrotic syndrome, who had received the highest cumulative and median daily glucocorticoid dose, possible disease-specific effects cannot be excluded. Interestingly, we found that the right hippocampal MD in patients reached values comparable to those of healthy controls the more time had elapsed since glucocorticoid treatment. This relationship was observed in both disease groups separately. Patients did not differ from controls in amygdalae MD. Finally, putamen volume was smaller in patients as compared to controls, a difference that was mainly driven by the children with rheumatic disease. Notably, putamen volume was smaller the older the children were when receiving glucocorticoid treatment.

The general lack of studies investigating the effect of glucocorticoid treatment in childhood and adolescence for extra-cerebral diseases on limbic and striatal grey matter structures makes it difficult to assess the validity and significance of our findings. Our observation of smaller right hippocampal volumes in patients as compared to healthy controls did not survive correction for multiple comparisons. Exploring if this difference might show anatomical specificity, by correcting for TBV, revealed that this likely was not the case. The latter would align with our previous finding in the same cohort with patients displaying significant smaller total brain volumes as compared to healthy controls ([@bb0145]). Overall, our failure to observe hippocampal volume differences may be rooted in e.g. insufficient statistical power, lack of anatomical specificity, and/or a lack of signal in hippocampal volume due to relatively low median daily glucocorticoid doses in combination with relative lengthy time since treatment. Nevertheless, our observation warrants further investigation given the available evidence suggesting that postnatal treatment with glucocorticoids affects hippocampal volume. In a study of preterm born children (gestational age at birth \<30 weeks), scanned at term-equivalent age (38--42 weeks\' postmenstrual age), postnatal exposure to glucocorticoids was found to predict smaller right and left hippocampal volumes corrected for intracranial volume ([@bb0270]). Moreover, adult patients with asthma or rheumatic diseases receiving long-term glucocorticoid treatment had smaller hippocampal volumes bilaterally as compared to patients with asthma or rheumatic diseases with minimal lifetime corticosteroid exposure ([@bb0035]). However, it is not clear whether this difference in volume is anatomically specific since the authors did not correct for either intracranial volume or TBV. Furthermore, in a recent study it was found that adult women treated with glucocorticoids due to congenital adrenal hyperplasia (CAH) had lower right hippocampal volumes (as well as smaller volumes in left and right thalami, cerebellum, and brainstem), corrected for TBV, as compared to healthy controls ([@bb0290]).

Our finding of lower right hippocampal MD in children previously treated with glucocorticoids compared to healthy controls seems to contrast with a recent report of increased MD in hippocampus as well as in multiple white matter fiber tracts, uncorrected for whole brain tissue MD, in women treated with glucocorticoids for CAH ([@bb0290]). However, studies are difficult to compare given the differences in stage of development, the type of disease studied, demographic characteristics of the study populations, and the applied methodologies. Grey matter MD is thought to be affected by cell density as in studies of tumour tissue lower MD was related to higher cell density ([@bb0030]; [@bb0065]; [@bb0125]). This suggests that lower right hippocampal MD in children previously treated with glucocorticoids may reflect an increase in the number of cellular elements. Such an interpretation, however, seems counter-intuitive given glucocorticoids\' known anti-proliferative effects ([@bb0175]; [@bb0225]). Furthermore, in a MR-spectroscopy study lower hippocampal *N*-acetyl aspartate ratio, representative of lower hippocampal neural cell densities, was observed in adults chronically treated with glucocorticoids for extra-cerebral diseases ([@bb0035]). Moreover, in animal models of perinatal glucocorticoid treatment, reduced neurogenesis occurred both shortly after the exposure as well as in the long-term ([@bb0170]; [@bb0220]). Neuron density, however, is not the only factor that can influence tissue MD. Factors such as level of myelination, cell sizes, number of dendrites, number of glial cells, inflammation or extracellular properties also play a role ([@bb0005]; [@bb0025]). Although speculatively, our finding of lower right hippocampal MD but not lower hippocampal volumes, may well reflect an increase in the number of glia cells ([@bb0075]). In support for this notion, a MR-spectroscopy study in adults with previously elevated endogenous glucocorticoid levels, due to Cushing\'s syndrome, reported lower hippocampal *N*-acetyl aspartate and higher glutamate and glutamine levels, suggestive of respectively reduced neuronal density and increased glial proliferation ([@bb0250]). Our observation that right hippocampal MD became more similar to that of healthy controls the more time had elapsed after termination of glucocorticoid treatment, suggests that this effect is, at least partly, reversible. The functional implications of our findings remain to be clarified. Since lower right hippocampal MD was more prominent in children with nephrotic syndrome than in those with rheumatic disease, we cannot rule out disease-specific effects. However, compared to the rheumatic group, the children with nephrotic syndrome had generally received higher glucocorticoid doses and the association between right hippocampal MD and time since glucocorticoid treatment was present in both disease-groups separately.

Given the widespread distribution of the glucocorticoid receptor throughout the brain ([@bb0050]) and its affinity of exogenous glucocorticoids such as prednisolone, we also investigated for possible group differences in striatal grey matter structures. Children previously treated with glucocorticoids had significantly smaller putamen volumes than healthy controls. Although preliminary, this finding seems to align with findings of a recent study of preterm born children treated with dexamethasone in neonatal life, who had smaller caudate nucleus and putamen volumes, as compared to preterm born children, who had not received dexamethasone treatment, 18 years after exposure ([@bb0070]). Moreover, a study in preterm fetal sheep found that exposure to glucocorticoids aggravated the neuronal injury following asphyxia in the hippocampus, but also in the putamen ([@bb0185]). However, smaller putamen volumes were most prominent in children with rheumatic diseases and the observed negative association between the median treatment age and putamen volume was absent in the children with nephrotic disorder. Since the children with rheumatic disease received lower cumulative and median daily dose of glucocorticoids than the children with nephrotic syndrome, our findings suggest that the observed smaller putamen volume may more likely be a disease-specific effect rather than due to the glucocorticoid treatment by itself. Furthermore, we may have lacked the statistical power to find smaller putamen volumes in patients with nephrotic syndrome given the lower number of patients with nephrotic syndrome in our study. Finally, it might also be that potential disease-specific findings are, at least partly, reflective of an uneven gender distribution in the two disease groups, with more girls among the children with rheumatic disease.

Overall, the present study is limited due to the relatively small sample sizes, as well as an uneven gender distribution in the two disease groups, with more girls among the children with rheumatic disease. Thus, we cannot exclude if the lack of specific hippocampal volume differences is due to a lack of statistical power. Moreover, by the very nature of our cross-sectional design we are not able to infer causality of previous glucocorticoid treatment, nor are we able to infer possible disease-related mechanism. Unfortunately, this inability to differentiate disease-specific effects from glucocorticoid treatment effects befalls most cross-sectional studies in patient populations. Furthermore, some participants also received other drugs such as TNFα-inhibitors or methotrexate. The most dominant non-glucocorticoid treatment at the time of assessment concerned TNFα-inhibitors. Interestingly, these have recently been found to prevent pharmacological neurotoxicity in the developing brain in rodents ([@bb0060]). Unfortunately, given the small number of patients receiving additional drug treatment, we were not able to address this issue in the current study and therefore cannot exclude the possibility that additional treatments may have influenced our results. Finally, an ideal control group would consist of patients with comparable disease histories, who had not been treated with glucocorticoids. However, it not possible to identify such a disease control group due to differences in disease mechanisms, course of illness, illness severity, and treatment. By including the two non-cerebral disease groups, we reasoned that effects common to both groups, specifically associations with glucocorticoid treatment variables, would be more reflective of glucocorticoid treatment than disease-specific effects.

In conclusion, we revealed for the first time that extra-cerebral diseases during childhood treated with glucocorticoids may be associated with reduced subcortical grey matter volumes and lower right hippocampal mean diffusivity later in life. While our results should be considered preliminary, they warrant replication and elaboration in larger, preferably prospective and longitudinal studies. Such studies would also allow disentangling disease-specific effects from glucocorticoid treatment effects.
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[^1]: SD = standard deviation. All *p*-values are derived from comparisons against controls. Gender differences were tested with Chi Square tests. Group differences in age and parent education were tested with independent samples *t*-tests. Patients (*n* = 27) and controls (*n* = 28) for whom diffusion weighted images were obtained did not differ in age (*t* = −1.3, *p* = .19), gender (*p* = .63), or parental education (*t* = 1.1, *p* = .29).

[^2]: Values are presented as median (range). Glucocorticoid treatment variables are expressed as prednisolone equivalents. Mann Whitney *U* tests were used to compare § Rheumatic group versus Nephrotic group and \# Girls versus Boys. *P* values \<.05 are displayed in italic bold.

[^3]: MD: mean diffusivity. Values are mean ± standard deviation. Volumes are given as mm^3^ if not stated otherwise and MD is given as 10^−6^ m^2^/s. Volume measures included 30 controls, 19 patients with rheumatic disease, and 11 with nephrotic syndrome. MD measures included 28 controls, 16 patients with rheumatic disease, and 11 with nephrotic syndrome.

[^4]: In models 1 (Degrees of freedom: = 3, 56), group, age and gender were used as independent variables. In models 2 (Degrees of freedom = 4, 55), group, age, gender and total brain volume (TBV) were used as independent variables. Negative β- values reflect lower volume in patients compared to controls or lower volume in girls compared to boys. Analyses included 30 patients and 30 controls. ROI = Region-of-interest. *R*^*2*^~*adj*~ = adjusted R-squared. P values \<.05 are displayed in italic bold. Effect sizes are expressed as squared semi-partial correlations (Sr^2^), which represent the proportion of the outcome variance that is associated uniquely with the predictor.

[^5]: Sr^2^~(model\ 1,\ right\ hippocampus,\ group)~ = 0.09.

[^6]: Sr^2^~(model\ 1,\ putamen,\ group)~ = 0.15.

[^7]: Sr^2^~(model\ 2,\ putamen,\ group)~ = 0.04.

[^8]: In models 1(Degrees of freedom: = 3, 56), group, age and gender were used as independent variables. In models 2 (Degrees of freedom: = 3, 56), group, age, gender and global MD were used as independent variables. Negative β-values reflect lower MD in patients compared to controls or lower MD in girls compared to boys. Analyses included 28 controls and 27 patients. ROI = Region-of-interest, M = Model, R = Right, L = Left. P values \<.05 are displayed in italic bold. Effect sizes are expressed as squared semi-partial correlations (Sr^2^), which represent the proportion of the outcome variance that is associated uniquely with the predictor.

[^9]: Sr^2^~(model\ 1,\ right\ hippocampus,\ group)~ = 0.07.

[^10]: Sr^2^~(model\ 2,\ right\ hippocampus,\ group)~ = 0.07.
